{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:14:11Z","timestamp":1794014051754,"version":"4.8.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T00:00:00Z","timestamp":1589328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.annonc.2020.05.001","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T09:05:57Z","timestamp":1589360757000},"page":"1001-1010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":190,"title":["Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"H.S.","family":"Rugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Toledano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Stemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Jurado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Juric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Ciruelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Campone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lteif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Gaudenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.05.001_bib1","doi-asserted-by":"crossref","first-page":"dju055","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.annonc.2020.05.001_bib2","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1002\/jcb.26687","article-title":"The prognostic value of PI3K mutational status in breast cancer: a meta-analysis","volume":"119","author":"Sobhani","year":"2018","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1016\/j.annonc.2020.05.001_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"issue":"Suppl 13","key":"10.1016\/j.annonc.2020.05.001_bib4","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1158\/1538-7445.AM2018-1207","article-title":"A\u00a0systematic literature review of the prevalence of PIK3CA mutations and mutation hotspots in HR+\/HER2- metastatic breast cancer","volume":"78","author":"Mollon","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.annonc.2020.05.001_bib5","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1056\/NEJMra1704560","article-title":"Phosphatidylinositol 3-kinase, growth disorders, and cancer","volume":"379","author":"Goncalves","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.001_bib7","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S1470-2045(17)30376-5","article-title":"Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Baselga","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.05.001_bib8","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1158\/1535-7163.MCT-13-0865","article-title":"Characterization of the novel and specific PI3K\u03b1 inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials","volume":"13","author":"Fritsche","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2020.05.001_bib9","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.05.001_bib10","series-title":"Piqray (alpelisib) [prescribing information]","year":"2019"},{"key":"10.1016\/j.annonc.2020.05.001_bib11","doi-asserted-by":"crossref","first-page":"e184475","DOI":"10.1001\/jamaoncol.2018.4475","article-title":"Alpelisib plus fulvestrant in PIK3CA-altered and PIK3CA-wild-type estrogen receptor-positive advanced breast cancer: a phase 1b clinical trial","volume":"5","author":"Juric","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2020.05.001_bib12","doi-asserted-by":"crossref","first-page":"LBA1006","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA1006","article-title":"Phase III study of taselisib (GDC-0032) plus fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): primary analysis from SANDPIPER","volume":"36","author":"Baselga","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.05.001_bib13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S1470-2045(17)30109-2","article-title":"Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial","volume":"18","author":"Rugo","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420397982?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420397982?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:57:38Z","timestamp":1760335058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420397982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0923753420397982"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.05.001","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}